【分享】世界临床在研抗癌新药目录

是个PDF文件，共60页！是2005年的资料，英文的！
部分内容如下
399 Medicines in Development Offer Hope in the War on Cancer
There are few things that cause patients more fear and
uncertainty as a cancer diagnosis. Yet today—
because of a steady stream of new and improved
medicines and treatments—cancer can increasingly be
managed and even beaten. Patients and their families are
looking for even more and better treatments, and America’s
research biopharmaceutical companies are responding.
Biopharmaceutical researchers are working on 399
medicines for cancer. Many are high-tech weapons that
fight the disease in new ways, while some involve
research on new ways to use existing medicines. The
research is being conducted by 178 pharmaceutical
and biotechnology companies and by the National
Cancer Institute.
The medicines in development—all in either clinical
trials or under Food and Drug Administration review—
include 62 for lung cancer, the leading cause of cancer
death in the United States; 49 for breast cancer, which is
expected to strike more than 200,000 American women
this year; 35 for colon cancer, the third most common
cancer in both men and women in this country; and 50 for
prostate cancer, which this year is expected to kill more
than 30,000 American men. Additional medicines target
kidney cancer, pancreatic cancer, brain cancer, skin cancer,
ovarian cancer, and others. In addition, companies are
working on medicines to improve the quality of life for
people undergoing cancer treatment.
This commitment to patients and research promises to
continue and accelerate the remarkable progress made in
the past decade against cancer, which led to declines in
both cancer cases and cancer deaths. Death rates for eight
of the top 10 cancers remained level or declined during
the 1990s, according to a Journal of the National Cancer
Institute report.

分享了，谢谢